Acrux Ltd (ASX: ACR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Acrux Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$13.08 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
290.72 million
Earnings per share
-0.002
Dividend per share
N/A
Year To Date Return
27.27%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Acrux Ltd (ASX: ACR)
Latest News
⏸️ Investing
Here's why these 4 stocks are soaring higher today
⏸️ Investing
Here's why you should avoid Australia's biotechnology sector
⏸️ Investing
Here's why Acrux Limited has crashed 43%
⏸️ Investing
4 ASX stocks tumbling today
⏸️ Investing
Here's why Acrux Limited crashed today
⏸️ Investing
Acrux Limited posts mixed half year: Should you buy?
⏸️ Investing
Acrux Limited reports quarterly results: Should you buy?
⏸️ Investing
Here's why investors are betting against these top-10 shorted stocks in 2015
⏸️ Investing
Here's why these 4 stocks are flying higher today
⏸️ Investing
Buyer beware: The 'professionals' say these ASX stocks are going to fall
⏸️ Investing
30 Aussie Magic Formula Picks for 2015
⏸️ Investing
Top stock picks for 2015
ACR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Acrux Ltd
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.
ACR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Nov 2024 | $0.05 | $0.00 | 0.00% | 25,000 | $0.05 | $0.05 | $0.05 |
| 21 Nov 2024 | $0.05 | $0.00 | 0.00% | 86,208 | $0.04 | $0.05 | $0.04 |
| 20 Nov 2024 | $0.05 | $0.00 | 0.00% | 4,010 | $0.05 | $0.05 | $0.05 |
| 19 Nov 2024 | $0.04 | $0.00 | 0.00% | 151,533 | $0.04 | $0.05 | $0.04 |
| 18 Nov 2024 | $0.04 | $0.00 | 0.00% | 73,893 | $0.04 | $0.04 | $0.04 |
| 15 Nov 2024 | $0.04 | $0.00 | 0.00% | 243,027 | $0.05 | $0.05 | $0.04 |
| 14 Nov 2024 | $0.05 | $0.00 | 0.00% | 198,925 | $0.05 | $0.05 | $0.04 |
| 12 Nov 2024 | $0.05 | $0.00 | 0.00% | 3,100 | $0.05 | $0.05 | $0.05 |
| 11 Nov 2024 | $0.05 | $0.00 | 0.00% | 324,978 | $0.05 | $0.05 | $0.05 |
| 08 Nov 2024 | $0.05 | $0.00 | 0.00% | 238,431 | $0.05 | $0.05 | $0.05 |
| 06 Nov 2024 | $0.05 | $0.00 | 0.00% | 432,245 | $0.05 | $0.05 | $0.05 |
| 05 Nov 2024 | $0.05 | $0.00 | 0.00% | 69,513 | $0.05 | $0.05 | $0.05 |
| 04 Nov 2024 | $0.05 | $0.00 | 0.00% | 14,000 | $0.05 | $0.05 | $0.05 |
| 01 Nov 2024 | $0.05 | $0.00 | 0.00% | 31,800 | $0.05 | $0.05 | $0.05 |
| 31 Oct 2024 | $0.05 | $0.00 | 0.00% | 387,073 | $0.05 | $0.05 | $0.05 |
| 30 Oct 2024 | $0.05 | $0.00 | 0.00% | 115,757 | $0.05 | $0.05 | $0.05 |
| 29 Oct 2024 | $0.06 | $0.00 | 0.00% | 8,917 | $0.06 | $0.06 | $0.06 |
| 28 Oct 2024 | $0.06 | $0.00 | 0.00% | 31,365 | $0.06 | $0.06 | $0.06 |
| 25 Oct 2024 | $0.06 | $0.00 | 0.00% | 133,443 | $0.05 | $0.06 | $0.05 |
| 24 Oct 2024 | $0.05 | $0.00 | 0.00% | 20,000 | $0.05 | $0.05 | $0.05 |
| 23 Oct 2024 | $0.05 | $0.00 | 0.00% | 136,860 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Mar 2024 | Ross Dobinson | Exercise | 418,851 | $23,036 |
Conversion of securities.
|
| 05 Mar 2024 | Ross Dobinson | Buy | 418,851 | $23,036 |
Conversion of securities.
|
| 05 Mar 2024 | Donald Brumley | Exercise | 265,736 | $14,615 |
Conversion of securities. 797,210 Unlisted Rights
|
| 20 Dec 2023 | Geoffrey Brooke | Exercise | 138,187 | $6,218 |
Conversion of securities. 1,062,946 rights
|
| 20 Dec 2023 | Geoffrey Brooke | Buy | 138,187 | $6,218 |
Conversion of securities.
|
| 20 Dec 2023 | Timothy Oldham | Exercise | 414,561 | $18,655 |
Conversion of securities. 1,062,946 unlisted rights
|
| 20 Dec 2023 | Timothy Oldham | Buy | 414,561 | $18,655 |
Conversion of securities.
|
| 05 Dec 2023 | Geoffrey Brooke | Issued | 1,062,946 | $52,084 |
Issue of securities. 12,01,133 Rights
|
| 05 Dec 2023 | Timothy Oldham | Issued | 1,062,946 | $52,084 |
Issue of securities. 14,77,507 Rights
|
| 05 Dec 2023 | Ross Dobinson | Issued | 1,675,405 | $82,094 |
Issue of securities. 1,675,405 unlisted rights
|
| 05 Dec 2023 | Donald Brumley | Issued | 1,062,946 | $52,084 |
Issue of securities. 1,062,946 Unlisted Rights
|
| 24 Nov 2023 | Ross Dobinson | Buy | 237,610 | $10,217 |
Conversion of securities.
|
| 24 Nov 2023 | Ross Dobinson | Exercise | 237,610 | $10,217 |
Conversion of securities.
|
| 24 Nov 2023 | Donald Brumley | Buy | 138,187 | $5,942 |
Conversion of securities.
|
| 24 Nov 2023 | Donald Brumley | Exercise | 138,187 | $5,942 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ross Dobinson | Non-Executive ChairmanNon-Executive Director | Jul 2012 |
Mr Dobinson has a background in investment banking and stockbroking. He was a founding Director of Starpharma Holdings Limited (ASX: SPL) and was formerly a Director of Reliance Worldwide Corporation (ASX: RWC), Executive Director of Hexima Limited (ASX: HXL), Chairman of TPI Enterprises Limited (now Palla Pharma Ltd. ASX: PAL), Director of Roc Oil Company Limited (ASX: ROC) and a Director of Racing Victoria Limited.
|
| Dr Geoffrey E.D Brooke | Non-Executive Director | Jun 2016 |
Dr Brooke has more than 30 years of venture capital experience. In 2014, he sold his involvement in GBS and now concentrates on privately investing in a small number of companies. He is a member of Risk and Human Capital Committee.
|
| Dr Timothy Oldham | Non-Executive Director | Oct 2013 |
Dr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is the Chair of the Human Capital Committee and also a member of Risk Committee.
|
| Mr Michael John Kotsanis | Chief Executive OfficerManaging Director | Nov 2014 |
Mr Kotsanis has more than 30 years of experience in the global pharmaceutical industry including significant senior leadership experience. Prior to Faulding, Michael held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11-year period.
|
| Mr Donald Charles Brumley | Non-Executive Director | Jun 2021 |
Mr Brumley has 30 years of experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. He is the Chair of the Risk Committee and also a member of Human Capital Committee.
|
| Ms Joanna Johnson | Chief Financial OfficerCompany Secretary | Jun 2021 |
-
|
| Joanna Johnson | Chief Financial OfficerCompany Secretary |
-
|
|
| Felicia Colagrande | Product Development and Technical Affairs Director |
-
|
|
| Mark Hyman | Project and Technical Development Director |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Phillip Asset Management Limited | 31,847,134 | 10.95% |
| Hishenk Pty Ltd | 11,000,000 | 3.78% |
| Mr Ross Dobinson | 5,249,245 | 1.81% |
| Dr Thomas Vui Chung Chai | 4,951,985 | 1.70% |
| Willoughby Capital Pty Ltd | 4,500,000 | 1.55% |
| Citicorp Nominees Pty Limited | 4,149,492 | 1.43% |
| Mr Christopher Murray Abbott | 4,000,000 | 1.38% |
| Ashwood River Pty Ltd | 3,800,000 | 1.31% |
| The Poole Family Superannuation Fund Pty Ltd | 3,700,000 | 1.27% |
| Mr Donald Charles Brumley | 3,396,108 | 1.17% |
| Netwealth Investments Limited | 3,284,269 | 1.13% |
| Mr Alan Jebb & Mrs Sandra Jebb | 3,100,000 | 1.07% |
| MNA Family Holdings Pty Ltd | 2,800,000 | 0.96% |
| TSO Pty Ltd | 2,625,734 | 0.90% |
| Mr Bikash Kaji Baniya | 2,339,711 | 0.80% |
| HSBC Custody Nominees (Australia) Limited | 2,100,674 | 0.72% |
| Pacific Custodians Pty Limited | 2,048,427 | 0.70% |
| Mr Ian Victor Lancini & Mrs Debra Ann Lancini | 2,045,000 | 0.70% |
| Mr Zirong Pu | 2,023,000 | 0.70% |
| Adam Jamal | 1,905,719 | 0.66% |
| Mr Michael John Kotsanis | 1,511,083 | 0.52% |
| Mr Allen James Kirby | 1,500,000 | 0.52% |
| Mr David Andrew Slobom & Mrs Linda Jane Slobom | 1,409,596 | 0.48% |
| NewEconomy Com Au Nominees Pty Limited | 1,327,870 | 0.46% |
| Mrs Nola Kendall Fletcher | 1,300,000 | 0.45% |
